LadRx (LADX) Float Percentage Of Total Shares Outstanding : 98.02% (As of Apr. 26, 2024)

View and export this data going back to 1986. Start your Free Trial

What is LadRx Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, LadRx's float shares is 0.49 Mil. LadRx's total shares outstanding is 0.50 Mil. LadRx's float percentage of total shares outstanding is 98.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, LadRx's Insider Ownership is 13.19%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, LadRx's Institutional Ownership is 0.00%.

LadRx Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

LadRx's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.49	/	0.50
	=	98.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx (LADX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049

Website

https://www.ladrxcorp.com

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

Executives

Cary J Claiborne	director	3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy	officer: Chief Executive Officer	C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson	director	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis	officer: Pres., Chief Operating Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz	officer: Vice President Drug Discovery	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d.	officer: Senior VP-Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware	officer: Chief Commercial Officer	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld	director	C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland	officer: Sr VP - Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro	director	11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049